Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (88791)	7/1/2002 8:17:14 AM
From: augieboo	Read Replies (1) \| Respond to of 99280

deridation??????

To: Zeev Hed who wrote (88791)	7/1/2002 8:18:12 AM
From: vampire	Respond to of 99280

IDPH down a bit premarket - Launch Delay for Radioimmunotherapy Product in the EU BERLIN, Jul 1, 2002 /PRNewswire-FirstCall from COMTEX/ -- Schering AG (FSE:SCH; NYSE: SHR chart, msgs) announced today that the launch of its radioimmunotherapy Zevalin(TM) (90Y-ibritumomab tiuxetan) in the EU will be delayed due to certain technical compliance issues at the fill/finish provider. Schering had originally hoped to launch the product in the second half of 2002. "We are examining all options to make this therapy available to patients as fast as possible," said Dr Joachim-Friedrich Kapp, Head of Schering AG's Specialized Therapeutics business area. "Zevalin(TM) is the first radioimmunotherapy treatment for certain Non-Hodgkin's Lymphoma and represents a significant step forward in the treatment of this disease. As the clinical efficacy of Zevalin(TM) is not in question we are confident to be able to launch Zevalin(TM) during the second half of 2003." Zevalin(TM), an anti-CD-20 antibody labeled with Yttrium 90, targets the CD20 antigen on the surface of the mature B-cells and B-cell tumors, inducing cellular damage in the target and neighboring cells. Zevalin (TM) has been approved for marketing by the U.S. Food and Drug Administration (FDA) in February 2002. Schering has exclusive worldwide marketing and distribution rights to Zevalin(TM), excluding the U.S., where IDEC Pharmaceuticals Corporation (Nasdaq: IDPH chart, msgs) retains its rights. The delay of the launch will not affect Schering's sales and earnings expectations in 2002. Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Fertility Control&Hormone Therapy, Diagnostics&Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work This press release has been published by Corporate Communication of Schering AG, Berlin, Germany